Legend Biotech Corporation
LEGN
Kedudukan dalam Saham
#4443
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Harga Saham
$19.04
Modal Pasaran
$3.52B
Perubahan (1 hari)
2.09%
Perubahan (1 tahun)
-42.15%
Negara
US
Perdagangan Legend Biotech Corporation (LEGN)
Kategori
Healthcare
Nisbah P/S bagi Legend Biotech Corporation (LEGN)
Nisbah P/S pada October 2026 TTM: 2.77
Menurut laporan kewangan dan harga saham terkini Legend Biotech Corporation, nisbah P/S semasa (TTM) ialah 2.77. Pada akhir 2023, nisbah P/S syarikat ialah 18.58.
Sejarah nisbah P/S untuk Legend Biotech Corporation dari 2017 hingga 2026
Nisbah P/S pada akhir setiap tahun
| Tahun | Nisbah P/S | Ubah |
|---|---|---|
| 2026 (TTM) | 2.77 | -41.57% |
| 2024 | 4.74 | -74.47% |
| 2023 | 18.58 | -45.24% |
| 2022 | 33.93 | -7.19% |
| 2021 | 36.56 | 66.30% |
| 2020 | 21.98 | -48.45% |
| 2019 | 42.65 | 13.26% |
| 2018 | 37.65 | -63.62% |
| 2017 | 103.51 | 0.00% |
Nisbah P/S untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/S | Perbezaan Nisbah P/S | Negara |
|---|---|---|---|
| 10.02 | 261.83% |
US
|
|
| 40.55 | 1,364.03% |
US
|
|
| 3.96 | 43.01% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 266.32% |
NL
|
